Interview with Philippe Ranty, Managing Director, Actavis France
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
As dermo-cosmetics inventors, Pierre Fabre Dermo Cosmetics innovates in skin care and hair care fields and solutions following a sacrosanct principle of beauty rooted in ethics.
Backed by a pharmaceutical laboratory, the key to our scientific excellence, Pierre Fabre designs dermo-cosmetic treatments according to the most rigorous criteria for efficacy and safety. At Pierre Farbe, we are focused on acquiring the most cutting-edge expertise and technology, particularly in natural substances, hydrotherapy in dermatology, biotechnologies, and sterile cosmetics.
Recommended by health care professionals, our dermo-cosmetic treatments are administered by staff trained in our beauty ethics approach, thus guaranteeing individually tailored solutions.
As specialists in dermatological therapy with Pierre Fabre Dermatology we are no. 1 in Europe and no. 2 globally on the dermo-cosmetics market, with sales of over €1 billion across 130 countries, and a portfolio of 10 complementary brands.
Pierre Fabre is committed to developing our brands in all parts of the world. Each brand in our portfolio has its own DNA and is positioned to target a different type skin types and needs. Our brands are based on natural active ingredients: thermal spring water for Avène, Rhealba® Oat for A-Derma, plant extracts for Klorane and Elancyl, essential oils and plant extracts for René Furterer. Our dermo-cosmetics products are developed, clinically tested and manufactured according to the standards set out by the pharmaceutical industry.
Contact
Pierre Fabre Dermo-Cosmetics
Les Cauquillous
81506 Lavaur Cedex
+33 149 10 81 68
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
US pharmaceutical companies have long been in the French market but in your experience how do you feel they have integrated the differences in culture? Is this a finished topic…
Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap…
See our Cookie Privacy Policy Here
